The wide overlap between the syndromes of chronic kidney disease (CKD) and chronic
heart failure (HF) means that familiarity with the 2021 European Society of Cardiology …

Heart failure (HF) is a complex, multifactorial and heterogeneous syndrome with substantial
mortality and morbidity. Over the last few decades, numerous attempts have been made to …

Heart failure (HF) represents a widespread health problem characterized by high morbidity
and mortality. Sacubitril/Valsartan (sac/val) has improved clinical prognosis in patients …

Objectives This study compared the efficacy and safety of sacubitril/valsartan to enalapril in
Black and non-Black Americans with acute decompensated heart failure (ADHF) …

Large randomized controlled trials (RCTs) have led to major changes in the treatment of
patients with heart failure and reduced left ventricular ejection fraction (HFrEF) and these …

Purpose Only a few studies are available on dose-related effects of sacubitril/valsartan
(angiotensin receptor neprilysin inhibition (ARNI)) in real-life patients with heart failure and …

Abstract Purpose of Review Acute heart failure (AHF) is among the leading causes for
unplanned hospital admission. Despite advancements in the management of chronic heart …

Aims Heart failure (HF) is one of the leading causes of cardiovascular morbidity and
mortality. HF with preserved ejection fraction (HFpEF), or diastolic failure, accounts for half of …

Heart failure (HF) has been classified in chronic HF (CHF) and acute HF (AHF). The latter
has been subdivided in acutely decompensated chronic HF (ADCHF) defined as the …

Purpose Patients affected by heart failure with reduced ejection fraction (HFrEF) receive
clinical and functional beneficial effects from treatment with sacubitril/valsartan. However …